In general, GITR crosslinking with agonistic antibodies enhances effector responses of the conventional CD4+ and CD8+ T cells both in the setting of chronic viral infections or tumor cell growth (Clouthier et al. 2014; Dittmer et al. 2004; Ko et al. 2005). Here, TNFRSF18 is linked to neoplasm.